The effect of a 7‐day delay in chemotherapy cycles on complete response and event‐free survival in good‐risk disseminated germ cell tumor patients Journal Article
| Authors: | Motzer, R. J.; Geller, N. L.; Bosl, G. J. |
| Article Title: | The effect of a 7‐day delay in chemotherapy cycles on complete response and event‐free survival in good‐risk disseminated germ cell tumor patients |
| Abstract: | The effect of duration of induction treatment on complete response (CR) and eventfree survival (EFS) (time to death or relapse) was evaluated in 162 “good‐risk” germ cell tumor (GCT) patients treated from November 1982 to July 1986 in a randomized prospective trial with VAB‐6 (cyclophosphamide + vinblastine + bleomycin + dactinomycin + cisplatin; 81 patients) versus etoposide + cisplatin (EP; 81 patients). Patients received three cycles of VAB‐6 every 28 days or four cycles of EP every 21 days. Treatment cycle with either regimen was routinely postponed for 7 days for leukocytes <3000/mm3 or platelets <100,000/mm3 and then administered regardless of blood count. The number of treatment days was calculated for each patient from initial treatment day to final induction date plus 28 days for VAB‐6 and plus 21 days for EP. The proportion of CR and the EFS for good‐risk GCT patients treated with cisplatin‐based chemotherapy were not influenced by a ≤7‐day delay resulting from chemotherapy‐induced myelosuppression. Short, planned delays in chemotherapy for good‐risk GCT patients (≤7 days per cycle) appear to be acceptable since they may prevent serious toxicity in this curable patient population. Delays of longer than 7 days are strongly discouraged except in extraordinary life‐threatening circumstances. Copyright © 1990 American Cancer Society |
| Keywords: | adolescent; adult; major clinical study; cisplatin; prospective studies; metastasis; bone marrow suppression; etoposide; antineoplastic combined chemotherapy protocols; drug administration schedule; risk factors; cyclophosphamide; vinblastine; randomized controlled trials; therapy delay; testicular neoplasms; dactinomycin; remission induction; bleomycin; neoplasms, germ cell and embryonal; regression analysis; germ cell tumor; middle age; human; male; priority journal; article; support, u.s. gov't, p.h.s. |
| Journal Title: | Cancer |
| Volume: | 66 |
| Issue: | 5 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 1990-09-01 |
| Start Page: | 857 |
| End Page: | 861 |
| Language: | English |
| DOI: | 10.1002/1097-0142(19900901)66:5<857::Aid-cncr2820660508>3.0.Co;2-g |
| PUBMED: | 1696846 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 27 January 2020 -- Source: Scopus |
Altmetric
Citation Impact
Related MSK Work